Cyprotex PLC Launch of New ADME Guide

TIDMCRX

Cyprotex PLC

15 October 2015

Cyprotex PLC

("Cyprotex" or "the Company")

Launch of New ADME Guide

Cyprotex PLC (AIM:CRX), a specialist ADME-Tox and Bioscience Contract Research Organisation, today announce the launch of their new ADME guide titled 'Everything you need to know about ADME'. ADME is an acronym for absorption, distribution, metabolism and excretion, which are the processes occurring to a pharmaceutical drug following dosing. Knowledge of these processes assist us in understanding drug concentrations in the blood and tissues within the body, which in turn influences efficacy, toxicity and potential drug-drug interactions.

Our original ADME guide was launched back in 2006 and since this time, Cyprotex have distributed thousands of copies to our fellow scientists in the industry. Because of developments in the industry over the past decade, the new guide, which is the 2(nd) edition, is very different to the original version, and contains largely new material. The new guide complements our existing 'Mechanisms of Drug-Induced Toxicity' guide and our 'DDI Regulatory Guidance' handbook.

Anthony Baxter PhD, Chief Executive Officer of Cyprotex, comments on the launch of the new ADME guide, 'We have been offering ADME services since the inception of the company in 1999. Through our corporate responsibility policy, we aim to share our experience and knowledge in the field for the benefit of our customers and wider scientific community. Our guides have proved extremely popular and provide a valuable resource for scientists in a range of disciplines who want to have an up-to-date overview of the current testing methods and how the data are interpreted in both a drug discovery and development setting .'

To request a copy of our new 'Everything you need to know about ADME' guide, please visit http://www.cyprotex.com/guides

For further information:

 
 Cyprotex PLC                         Tel: [phone] 
                                       505 100 
 Dr Anthony Baxter, Chief Executive   [e-mail] 
  Officer                              www.cyprotex.com 
  John Dootson, Chief Financial 
  Officer 
  Mark Warburton, Chief Operating 
  Officer and Legal Counsel 
 
 N+1 Singer (Nomad and broker to      Tel: [phone] 
  Cyprotex)                            3000 
 Shaun Dobson                         [e-mail] 
  Jen Boorer                           [e-mail] 
                                       www.n1singer.com 
 

Notes to Editors

About Cyprotex PLC

Cyprotex is listed on the AIM market of the London Stock Exchange (CRX). It has sites at Macclesfield and Alderley Park, both of which are near Manchester in the UK, and at Watertown, MA and Kalamazoo, MI in the US. The Company was established in 1999 and works with more than 1200 partners within the pharmaceutical and biotech industry, cosmetics and personal care industry and the chemical industry. Cyprotex acquired Apredica and the assets of Cellumen Inc. in August 2010 and the combined business provides support for a wide range of experimental and computational ADME-Tox and PK services. The acquisition of the assets and business of CeeTox in January 2014 has enabled Cyprotex to expand its range of services to target the personal care, cosmetics and chemical industries.

In 2015, Cyprotex launched its new bioscience division to expand its capabilities into phenotypic and target based screening. The Company's core capabilities include high quality in vitro ADME screening services, mechanistic toxicology and high content toxicology screening services, including our proprietary CellCiphr(R) toxicity prediction technology, bioscience services, predictive modelling using PBPK, including Cloe(R) PK for in vivo PK prediction, and a range of skin, ocular and endocrine disruption services. For more information, see www.cyprotex.com.

This information is provided by RNS

The company news service from the London Stock Exchange

END

NRABXBDGBSBBGUS

(END) Dow Jones Newswires

October 15, 2015 02:00 ET (06:00 GMT)